ALK and non-small cell lung carcinoma: Indeed, in preclinical studies, it has been shown that crizotinib elicits beneficial effects in combination with radiotherapy in ALK-positive NSCLC cell lines by reducing tumor proliferation, microvascular density and perfusion [18,19].